GlassScriptPhysician profile
Douglas A Rennert
NPI 1992796502
$13,744.55
in general payments reported to CMS, 2019-2025
40 companies · $2,910 in 2025
The $2,910 reported for 2025 was more than what 82% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,268 · 2020: $1,728 · 2021: $1,626 · 2022: $1,605 · 2023: $2,372 · 2024: $2,236 · 2025: $2,910.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,407 · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,407.30 |
| Education | $111.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,549.53 | 2019-2025 | Airsupra, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $2,229.61 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $1,558.07 | 2019-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $833.30 | 2019-2025 | Ofev, Jascayd |
| Inspire Medical Systems, INC. | $731.06 | 2021-2025 | Inspire |
| Mylan Specialty L.P. | $555.95 | 2019-2024 | Yupelri |
| Harmony Biosciences LLC | $519.44 | 2020-2025 | Wakix |
| Takeda Pharmaceuticals U.S.A., INC. | $424.82 | 2021-2025 | Glassia |
| Insmed, INC. | $409.28 | 2019-2025 | Arikayce |
| Genzyme Corporation | $357.76 | 2019-2025 | |
| Grifols USA, LLC | $270.44 | 2019-2025 | Prolastin-C Liquid |
| Philips North America LLC | $198.70 | 2019-2022 | |
| Amgen INC. | $194.81 | 2021-2025 | Tezspire |
| Axsome Therapeutics, INC. | $170.66 | 2023-2025 | Sunosi |
| Genentech USA, INC. | $165.29 | 2019-2022 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $163.27 | 2019-2020 | |
| United Therapeutics Corporation | $144.69 | 2022-2025 | Tyvaso, Tyvaso |
| Teva Pharmaceuticals USA, INC. | $141.03 | 2019-2023 | Airduo Digihaler |
| Merck Sharp & Dohme LLC | $133.35 | 2020-2025 | Zerbaxa, Belsomra |
| Eisai INC. | $111.87 | 2021 | |
| Baxter Healthcare | $101.04 | 2023-2024 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Electromed, INC. | $91.04 | 2022-2024 | Smartvest |
| Pulmonx Corporation | $67.75 | 2023 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Shionogi INC | $67.72 | 2024 | Fetroja |
| Viatris Specialty LLC | $67.30 | 2025 | Yupelri |
| Avadel Cns Pharmaceuticals, LLC | $66.34 | 2025 | Lumryz |
| Astellas Pharma US INC | $63.79 | 2019-2025 | Cresemba |
| Mallinckrodt Hospital Products INC. | $52.26 | 2022-2023 | Acthar |
| Circassia INC. | $36.82 | 2019 | |
| Sunovion Pharmaceuticals INC. | $35.93 | 2019 | |
| Jazz Pharmaceuticals INC. | $30.02 | 2019-2024 | |
| Vifor Pharma, INC. | $29.86 | 2024 | Zemaira |
| Lilly USA, LLC | $25.00 | 2025 | Zepbound |
| Pfizer INC. | $24.58 | 2023 | |
| Csl Behring | $24.46 | 2020 | |
| Novartis Pharmaceuticals Corporation | $22.90 | 2021 | |
| Inogen, INC. | $22.25 | 2022 | |
| Nabriva Therapeutics, Plc | $21.30 | 2022 | |
| 3b Medical, INC. | $15.79 | 2025 | Luna |
| Fisher & Paykel Healthcare INC | $15.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Rennert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.